Effect of Multiple Injections of Small Divided Doses Vs Single Injection of Intravitreal Bevacizumab on Retinal Neovascular Model in Rabbits

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2009 Aug 1

PMID 19644699

Citations 4

Authors

Saloomeh Saati

Rajat N Agrawal

Stan Louie

Gerald J Chader

Mark S Humayun

Affiliations

Soon will be listed here.

Abstract

Background: To compare effects of multiple injections of small divided doses of intravitreal bevacizumab vs a single injection using a retinal neovascular model in rabbits.

Methods: We assigned 12 pigmented rabbits to four groups of three each. All groups received an intravitreal injection of vascular endothelial growth factor (VEGF, 10 microg) on the first day. Group A received an intravitreal loading dose of bevacizumab (0.5 mg) on day 3, followed by five smaller injections (0.15 mg), one every third day. Those in groups B and C received a single intravitreal injection of bevacizumab (1.25 mg) on day 3, followed by five injections of sham, one every third day in group C. Group D received only intravitreal VEGF. Follow-up examinations were performed for 26 days.

Results: In groups A and B, vascular changes associated with VEGF injection decreased substantially in the first 3 days, and continued to show gradual regression during each follow-up interval. No statistically significant differences were found between the changes of mean retinal thicknesses in groups A and B in both areas. In group C, the extra sham injections did not lead to any further vascular changes. The mean retinal thickness in groups B and C did not have a statistically significant difference during the follow-up period. In group D, vascular changes resolved more gradually than in other groups. The difference in retinal thickness between group D and the other groups was statistically significant on day 6 in both groups (medullary and inferior part; p = 0.0003) and in medullary wing on day 12 (p = 0.03).

Conclusions: Frequent smaller doses of bevacizumab can control VEGF-induced vascular changes as well as the currently utilized model of single large monthly injections. Dividing of currently used single injection (1.25 mg) of bevacizumab to multiple small doses can control VEGF-induced vascular changes as effectively as one large injection.

Citing Articles

Nuclear factor kappa-B signaling is integral to ocular neovascularization in ischemia-independent microenvironment.

DeNiro M, Al-Mohanna F PLoS One. 2014; 9(7):e101602.

PMID: 25050547 PMC: 4106825. DOI: 10.1371/journal.pone.0101602.

Micro- and nano-fabricated implantable drug-delivery systems.

Meng E, Hoang T Ther Deliv. 2013; 3(12):1457-67.

PMID: 23323562 PMC: 3576846. DOI: 10.4155/tde.12.132.

MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications.

Meng E, Hoang T Adv Drug Deliv Rev. 2012; 64(14):1628-38.

PMID: 22926321 PMC: 3488150. DOI: 10.1016/j.addr.2012.08.006.

Fluorescein angiography, optical coherence tomography, and histopathologic findings in a VEGF(165) animal model of retinal angiogenesis.

Arana L, Pinto A, Chader G, Barbosa J, Morales S, Moreira A Graefes Arch Clin Exp Ophthalmol. 2012; 250(10):1421-8.

PMID: 22427240 DOI: 10.1007/s00417-012-1978-8.

References

Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S . Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008; 115(10):1750-5, 1755.e1. DOI: 10.1016/j.ophtha.2008.04.023. View

Rahimi N . Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res. 2006; 83(5):1005-16. PMC: 1576298. DOI: 10.1016/j.exer.2006.03.019. View

Simo R, Hernandez C . Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008; 51(9):1574-80. DOI: 10.1007/s00125-008-0989-9. View

Feiner L, Barr E, Shui Y, Holekamp N, Brantley Jr M . Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006; 26(8):882-8. DOI: 10.1097/01.iae.0000230717.85319.f5. View

Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R . Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26(9):999-1005. DOI: 10.1097/01.iae.0000247165.38655.bf. View

Avery R . Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26(3):352-4. DOI: 10.1097/00006982-200603000-00016. View

Wong C, Rich K, Liaw L, Hsu H, Berns M . Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res. 2001; 22(2):140-7. DOI: 10.1076/ceyr.22.2.140.5528. View

Yancopoulos G, Davis S, Gale N, Rudge J, Wiegand S, Holash J . Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407(6801):242-8. DOI: 10.1038/35025215. View

Ozaki H, Hayashi H, Vinores S, Moromizato Y, Campochiaro P, Oshima K . Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997; 64(4):505-17. DOI: 10.1006/exer.1996.0239. View

10.

Bhisitkul R . Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006; 90(12):1542-7. PMC: 1857529. DOI: 10.1136/bjo.2006.098426. View

11.

Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt K . Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007; 143(6):995-1002. DOI: 10.1016/j.ajo.2007.03.007. View

12.

Inan U, Avci B, Kusbeci T, Kaderli B, Avci R, Temel S . Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007; 48(4):1773-81. DOI: 10.1167/iovs.06-0828. View

13.

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

14.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

15.

Wells J, Murthy R, Chibber R, Nunn A, Molinatti P, Kohner E . Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996; 80(4):363-6. PMC: 505466. DOI: 10.1136/bjo.80.4.363. View

16.

Caldwell R, Bartoli M, Behzadian M, El-Remessy A, Al-Shabrawey M, Platt D . Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003; 19(6):442-55. DOI: 10.1002/dmrr.415. View

17.

Finger P . Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol. 2007; 143(2):335-8. DOI: 10.1016/j.ajo.2006.09.014. View

18.

Rosenfeld P, Fung A, Puliafito C . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005; 36(4):336-9. View

19.

Spaide R, Fisher Y . Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26(3):275-8. DOI: 10.1097/00006982-200603000-00004. View

20.

Pournaras C, Rungger-Brandle E, Riva C, Hardarson S, Stefansson E . Regulation of retinal blood flow in health and disease. Prog Retin Eye Res. 2008; 27(3):284-330. DOI: 10.1016/j.preteyeres.2008.02.002. View